The present invention relates to compositions and methods relating to MEK5 and
its role in heart disease. This protein has now been identified as a target for
therapeutic intervention due to its role molecular events that lead to or contribute
to cardiac hypertrophy and/or dilated cardiomyopathy. In particular, inhibition
of MEK5 activity will lead to decrease signalling of the pathways and reduce or
eliminate the effects on sarcomere assembly, which in turn result or contribute
to cardiac dysfunction. Also provided are transgenic animals and methods of screening
for inhibitors of MEK5.
